Metraipolis › archive › dc_c0a5833bd2b5

Efficacy and safety of immune checkpoint inhibitors combined with tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma: a… — Europe PMC PMID:42220544

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42220544
DOI
10.3389/fimmu.2026.1805039
License (as archived)
solo-consultazione
Archived
2026-11-01T16:37:33.456Z
SHA-256 of the archived text
2c965e6ff2bb7572de0a8a5d1afcbca62865e49afdf8552f79b77f5db6593df2
Stable URL of this page
https://metraipolis.com/documento/dc_c0a5833bd2b5

How to cite

Efficacy and safety of immune checkpoint inhibitors combined with tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma: a… — Europe PMC PMID:42220544 — Europe PMC (en), https://europepmc.org/article/MED/42220544 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_c0a5833bd2b5 (Metraipolis archive dc_c0a5833bd2b5, sha256 2c965e6ff2bb7572de0a8a5d1afcbca62865e49afdf8552f79b77f5db6593df2)
BibTeX
@misc{dcc0a5833bd2b5,
  title = {Efficacy and safety of immune checkpoint inhibitors combined with tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma: a… — Europe PMC PMID:42220544},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42220544},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_c0a5833bd2b5; sha256 2c965e6ff2bb7572de0a8a5d1afcbca62865e49afdf8552f79b77f5db6593df2},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42220544. Agents can read the archived copy with the MCP tool read_document.